Halozyme Therapeutics, Inc. (HALO) fair value analysis

Nasdaq · Updated 2026-09-07

Halozyme Therapeutics, Inc. is a biopharmaceutical company that develops and commercializes technologies and therapeutic products focused on oncology, immunology, and other therapeutic areas. The company operates in the United States and internationally, conducting research, development, manufacturing, and sales activities across multiple regions.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, HALO is trading at more than a 25% discount to estimated fair value.

HALO currently ranks #14 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $82.27
Sector: Healthcare
12-month range: $63.96–$82.27

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Momentum grade: A
Leverage: High
Margin trend: Expanding
Revenue growth: High
RSI zone: Overbought
50/200-day trend: Mixed
52-week position: The top quarter of its range
DCF cross-check: Fairly Valued

What our data shows for HALO

Our model validated 17 trailing price-to-earnings windows for HALO, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $63.96–$82.27.
The 14-day relative strength index sits at an overbought 78.
3 of the last 12 weekly snapshots showed positive price momentum.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for HALO
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent HALO news

TickrTrends' derived news-sentiment signal for HALO is currently leaning positive, computed from recent coverage.

Halozyme: The Market May Be Underpricing The Second Growth Wave (NASDAQ:HALO) (seekingalpha.com, 2026-09-01)
TickrTrends take: Halozyme operates in the Healthcare sector where valuation multiples can compress during periods of growth uncertainty, and TickrTrends currently assesses the stock as undervalued relative to its fundamentals. The headline's reference to a potential second growth wave suggests the market may not have fully incorporated future revenue drivers into the current stock price, which aligns with the undervalued assessment. Investors focused on valuation should monitor whether the company can demonstrate execution on its growth initiatives, as this would validate whether current pricing truly reflects the company's earnings potential.
Halozyme Therapeutics: Running Through 2027 (NASDAQ:HALO) (seekingalpha.com, 2026-08-24)
TickrTrends take: Halozyme Therapeutics trades with an Undervalued designation from TickrTrends despite operating in the competitive Healthcare sector, suggesting the market may not be fully pricing in the company's prospects through 2027. For valuation-focused investors, monitoring how the company executes its pipeline and revenue growth over the coming years will be critical to validating whether current pricing accurately reflects long-term value creation. The extended planning horizon referenced in the headline indicates management confidence in sustained operations, which could support the case for continued undervaluation if financial performance meets or exceeds expectations.
Incyte Corporation (INCY) has the Bigger Revenue Base, but Could Halozyme Therapeutics, Inc. (HALO) have the Better Economics? (finance.yahoo.com, 2026-08-14)
TickrTrends take: Halozyme Therapeutics operates in the Healthcare sector where revenue scale alone does not determine economic efficiency or profitability potential. TickrTrends' Undervalued designation suggests the market may not be fully pricing in HALO's ability to generate returns on its asset base relative to its current valuation. Investors focused on valuation should monitor whether HALO can demonstrate superior unit economics and margin expansion compared to larger competitors like Incyte, as these operational metrics would support the undervaluation thesis.

What people are saying

Follow the HALO conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is HALO stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), HALO is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is HALO's TickrTrends verdict?

HALO's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does HALO compare to other Healthcare stocks?

HALO ranks #14 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is HALO overbought or oversold?

HALO's 14-day RSI is in the overbought zone on TickrTrends' latest weekly data.

All Healthcare fair-value coverage →

Head-to-head comparisons

HALO vs ALGN · HALO vs AMPH · HALO vs ANIP · HALO vs BSX · HALO vs COO